Academic Journal
Talimogene laherparepvec treatment to overcome loco-regional acquired resistance to immune checkpoint blockade in tumor stage IIIB–IV M1c melanoma patients
| Title: | Talimogene laherparepvec treatment to overcome loco-regional acquired resistance to immune checkpoint blockade in tumor stage IIIB–IV M1c melanoma patients |
|---|---|
| Authors: | Fröhlich, Anne, Niebel, Dennis, Fietz, Simon, Egger, Eva, Buchner, Andrea, Sirokay, Judith, Landsberg, Jennifer |
| Source: | http://lobid.org/resources/99370671253406441#!, 69(5):759-769. |
| Publication Year: | 2020 |
| Collection: | Publisso (ZB MED-Publikationsportal Lebenswissenschaften) |
| Subject Terms: | Melanoma/therapy [MeSH], Costimulatory and Inhibitory T-Cell Receptors/antagonists, Disease Progression [MeSH], Aged, 80 and over [MeSH], Aged [MeSH], Progression-Free Survival [MeSH], Antineoplastic Agents, Immunological/pharmacology [MeSH], Advanced melanoma, Oncolytic Virotherapy/methods [MeSH], Original Article, Neoplasm Staging [MeSH], Immunotherapy/methods [MeSH], Male [MeSH], Melanoma/pathology [MeSH], Targeted therapy, Skin Neoplasms/immunology [MeSH], Female [MeSH], Follow-Up Studies [MeSH], Drug Resistance, Neoplasm/drug effects [MeSH], Adult [MeSH], Humans [MeSH], Retrospective Studies [MeSH], Middle Aged [MeSH], Skin Neoplasms/pathology [MeSH], Neoplasm/immunology [MeSH], Melanoma/mortality [MeSH], Herpesvirus 1 |
| Description: | Background!#!Resistance to immune checkpoint blockade and targeted therapy in melanoma patients is currently one of the major clinical challenges. With the approval of talimogene laherparepvec (T-VEC), oncolytic viruses are now in clinical practice for locally advanced or non-resectable melanoma. Here, we describe the usage of T-VEC in stage IVM1b-M1c melanoma patients, who achieved complete remission or stable disease upon systemic treatment but suffered from a loco-regional recurrence. To our knowledge, there are no case reports so far describing T-VEC as a means to overcome acquired resistance to immune checkpoint blockade or targeted therapy.!##!Methods!#!All melanoma patients in our department treated with T-VEC in the period of 2016-2018 were evaluated retrospectively. Data on clinicopathological characteristics, treatment response, and toxicity were analyzed.!##!Results!#!Fourteen melanoma patients were treated with T-VEC in our center. Six patients (43%) received T-VEC first-line. In eight patients (57%), T-VEC followed a prior systemic therapy. Three patients with M1b stage and one patient with M1c stage melanoma were treated with T-VEC. These patients suffered from loco-regional progress, whilst distant metastases had regressed during prior systemic treatment. 64% of patients showed a benefit from therapy with T-VEC. The durable response rate was 36%.!##!Conclusion!#!T-VEC represents an effective and tolerable treatment option. This is true not only for loco-regionally advanced melanoma patients, but also for patients with stable or regressive systemic metastases who develop loco-regionally acquired resistance upon treatment with immune checkpoint blockade or targeted therapy. A sensible selection of suitable patients seems to be crucial. |
| Document Type: | article in journal/newspaper |
| Language: | English |
| Relation: | https://repository.publisso.de/resource/frl:6470336; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7183503/ |
| DOI: | 10.1007/s00262-020-02487-x |
| Availability: | https://repository.publisso.de/resource/frl:6470336 https://doi.org/10.1007/s00262-020-02487-x https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7183503/ |
| Rights: | https://creativecommons.org/licenses/by/4.0/ |
| Accession Number: | edsbas.C9E9715E |
| Database: | BASE |
| DOI: | 10.1007/s00262-020-02487-x |
|---|